#Genetically #modified #vaccine #puppies
The Government authorized the marketing of a new transgenic vaccine against two viral diseases that affect puppies (Illustrative image Infobae)
The government granted permission for the marketing of a genetically modified vaccine to prevent distemper and parvovirus. It is intended for puppies between 4 and 6 weeks old and will allow them to produce a protective immune response against both diseases. In addition, it will prevent the spread of viruses after infection.
Distemper and canine parvovirus are viral diseases that affect young puppies, and are very contagious, in addition to presenting high morbidity, that is, many infected animals, and high mortality.
For the first time in Argentina, a transgenic vaccine is authorized to immunize dogs up to 6 weeks old against two viral diseases (iStock)
Distemper “affects many organs, including the nervous system, and spreads through eye and nose secretions of infected dogs,” the Bioeconomy Secretariat reports.
It is a virus that is very resistant to disinfectants, which causes intestinal and cardiac problems. It is eliminated in the fecal matter of sick dogs, which are usually young.
Infected dogs shed viral particles in their fecal mattercontaminating the environment, where it can survive for more than six months
Some of the symptoms presented by dogs infected are lack of appetite and fever. And after one or two days, they experience vomiting and bloody diarrhea, which causes dehydration and can lead to the death of the animal.
Because it is a highly lethal disease with low chances of survival even with treatment, the best option against parvovirus is prevention through vaccination.
If you have any questions, it is best to consult with the puppy’s primary veterinarian, who will be able to evaluate risks and recommend the best vaccination strategy based on the needs.
To date, the existing vaccines on the Argentine market to prevent both diseases are not genetically modified (Illustrative Image Infobae)
To date, the existing vaccines on the Argentine market to prevent both diseases are not genetically modified, while they are already being implemented in Europe and other regions of the world. Therefore, this authorization promotes technological advancement for the development of GMO vaccines.
.png)
